
A 60-second, ₹100 retinal scan that screens for 10 life-threatening conditions


Anand Sivaraman
Anand Sivaraman
In India, more than 20 million people are at risk of vision loss from retinal diseases, around 220 million face hypertension risk, over 80 million live with diabetes, and more than 195 million are affected by CVD and CKD. Over 20 million women experience pregnancy-related conditions, including preeclampsia, gestational diabetes, and anaemia. This gap highlights the need for a low-cost, point-of-care platform capable of screening multiple high-burden conditions through a single device and unified workflow.


With a single retinal scan lasting about 60 seconds and costing roughly ₹100, Remidio’s innovation screens for 10 conditions at once: eye diseases (diabetic retinopathy, glaucoma and age-related eye degeneration) and systemic conditions, including diabetes, hypertension, cardiovascular disease, chronic kidney disease, anaemia and gestational diabetes. Powered by offline AI, it works without the internet, without a lab, and without an ophthalmologist on site.
Deployed devices worldwide
Million screening patients
Across countries
Scale


